Observational studyFrontiers in neurology2026
Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States.
Observational study in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Short-term prevention (STP) is a targeted treatment approach to minimize migraine attacks during specific, time-limited periods. Because migraine disproportionately affects women, this study evaluated sex-related differences in the context of rimegepant for STP. Methods: A cross-sectional observational study collected real-world data via an online survey. Eligible subjects were US residents aged ≥18 years with self-reported episodic or chronic migraine, receiving rimegepant, initiated ≥3 months, and taken within 30 days of survey completion. Reported Results: Of 425 adults, 152 used rimegepant for STP (female, Conclusion: This study highlights how migraine differentially affects women and men. Subtle variations by sex in factors provocative of a migraine attack and reasons for rimegepant use were observed. Regardless of sex, rimegepant has potential for STP of migraine. Women and men reported high levels of satisfaction with rimegepant for STP when taken as needed, every other day, or every day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.